Your SlideShare is downloading. ×
Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

2,043
views

Published on

EuroBioForum 2012 | 18 April 2012 …

EuroBioForum 2012 | 18 April 2012
Presentation by Merja Hiltunen, Research and Innovation Counsellor at the Finnish Liaison Office for EU R&D of Tekes

Published in: Business, Technology

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,043
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Finnish perspective to the Personalised Medicine while Bridging towards Horizon 2020 EuroBioForum 2012, 18 April Merja Hiltunen, MD, PhD Counsellor, Research and Innovation Tekes Brussels Office Embassy of Finland DM 913958 10-2011 Copyright © Tekes
  • 2. Tekes the Finnish Funding Agencyfor Technology and Innovation DM 607668 03-2011 Copyright © Tekes
  • 3. Public sector activities of R&D in Finland PARLIAMENT Research and Innovation GOVERNMENT Council Ministry of Ministry of Other Education and Employment ministries Culture and the and their Economy institutes Academy Sitra of Tekes Finnvera plc Finland Finpro VTT, Finnish Technical Industry Universities Research Investment Ltd Centre Regional ELY-Centres Copyright © Tekes
  • 4. Tekes R&D funding in 2011Total 610 milj. € euros and 1 928 projects Funding for SHOK R&D grants research programmes to companies and 81 milj. €public organisations 225 milj. € Research funding for universities, research institutes and polytechnics 203 milj. € R&D loans for companies 101 milj. € The funding for R&D includes 18 million euros from EU Structural Funds. Research programmes of the Strategic Centres for Science, Technology and Innovation (SHOK) are joint programmes for research organisations and companies. DM 840918 ja 450969 01-2012 Copyright © Tekes
  • 5. Focus areas of Tekes strategyBusiness in globalvalue networks Natural resources and sustainable economyValue creation based on servicesolutions and intangible assets Intelligent Vitality environments of peopleRenewing services andproduction by digital means Strategic research areas determined by the Strategic Centres for Science, Technology and Innovation DM 909717 Copyright © Tekes
  • 6. 1) What is the state of affairs in PersonalisedMedicine in your region / country / organisation? Tekes Pharma Programme (2008-2011) promoted personalised medicine by funding research and development public and company projects where new molecular biology tools and biomarkers were developed for diagnostic purposes. • The programme strengthened cooperation with pharmaceutical non-clinical and clinical research networks and funded the development of a national operations model for clinical research in Finland. FiDiPro – Finland Distinguished Professor Programme implemented and financed by the Academy of Finland and Tekes, provides competitive grants to projects recruiting both international and expatriates, highly merited scientists who are able to commit to long- term cooperation with a Finnish university or research institute. • With respect to Personalised Medicine, Tekes has funded two FiDiPro projects, which will continue until the end of the year 2014. DM 10-2011 Copyright © Tekes
  • 7. Pharma Programme themes (2008-2011) Predictive models and methods Chemical production technologyPharma accelerating and supporting and innovative medical the drug development process formulations  Patient samples and registry data  Solutions for synthesis and development to support research of cost effective synthetic pathways  Identifying and exploiting biomarkers  New production technologies for  Understanding pathogenetic promising drug candidates and generic mechanisms as well as pharmaco- medicines kinetics and mechanisms of action  Innovative drug formulations for children, the elderly and for veterinary use  Drug delivery technologies The development of a Networked business models national operational model  Developing business skills for clinical drug research  Production of innovations and  Reformation and harmonisation access of new products to the of clinical processes and market operations  Development of therapy-specific clusters Copyright © Tekes
  • 8. FinnTrials - Tekes funded Pharma Programme project offive Finnish University hospitals Project aims to develop a national operational model with internet based supportive administrative services for clinical research The project will create unified principles of action and the single point of access to speed the feasibility of clinical trials in Finland FinnTrials has made possible for national clinical research organisations to operate as a network in Finland to achieve better results of each hospital district projects Connections has been built to ECRIN (European Clinical Research Infrastructures Network) collaborations, too Copyright © Tekes
  • 9. Personalised Medicine as a part of FiDiPro ProgrammeFiDiPro project 1:“Translational Research and Personalised Medicine”• FiDiPro Professor Jonathan Knowles• Finnish host organisation: University of Helsinki, Institute for Molecular Medicine Finland (FIMM); Director, Professor Olli Kallioniemi DM 10-2011 Copyright © Tekes
  • 10. Personalised Medicine as a part of FiDiPro programmeFiDiPro project 2:“Systems Biology of Cancer: Mapping, Methods and Modeling forthe Cancer Genome” FiDiPro Professor Wei Zhang Finnish host organisation: Tampere University of Technology, Department of Signal Processing; Professor Olli Yli-Harja DM 10-2011 Copyright © Tekes
  • 11. Vitality of peoplePriorities• Health promotion • Preventive healthcare • Personalised solutions for wellbeing • Intelligent monitoring • Utilization of data resources• Efficient and high-quality social and health care service system• Work and learning that regenerate human skills and capabilities• Affective and meaningful free time experiences DM 909717 Copyright © Tekes
  • 12. Vitality of peopleCurrent priority: Personalised health and wellbeingTekes Call for proposals 1.1- 28.2.2012 CLOSED- Strategic openings of research groups-Public research-Excellence and high level competences for future businesses DM 10-2011 Copyright © Tekes
  • 13. 2) What are the challenges for your region /country / organisation? Implementing personalised medicine will require a high degree of collaboration amongst the many stakeholders in the life science and medical sectors Implementation of Medicines Policy 2020 of Ministry of Social Affairs and Health • The document Medicines Policy 2020 (Towards efficient, safe, rational and cost-effective use of medicines) reports on the joint objectives of the social welfare and healthcare authorities and stakeholders in the field of medicines by the year 2020. National network and operating model for biobanks is needed • Strategic plan and vision • Resources needed • Competitive knowledge and business base. Efforts by academia and industry need to be stepped up • Biobank Act is intended to come into force in Finland at the beginning of 2013. It sets new standards on research use of human origin • European level collaboration (eg. Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) is important, too Copyright © Tekes
  • 14. Horizon 2020 - Priorities for Tekes1. Broad concept of innovation2. New forms of innovation activities and user-orientation3. SME-instrument (and other SME funding modalities)4. Key enabling competences5. Evaluation with various excellence criteriaHorizon 2020 has excellent starting point, orientation and target. 03- DM 369407 Copyright © Tekes 2008
  • 15. 3) What is your expectation of the Horizon 2020programme and where do you see opportunities forcollaboration? Health, demographic change and wellbeing • Corresponding elements and themes in Horizon 2020 as in our strategy Research infrastructures • Access to high-level infrastructures (such as BBMRI and Elixir) - valuable SME involvement • Strategic investments in key enabling technologies – key competencies Innovative Medicines Initiative (IMI) • According to the Horizon 2020 proposal, existing public-private partnerships (PPPs) like IMI may continue to receive support - an opportunity for collaboration FET Flagships - potential DM 10-2011 Copyright © Tekes
  • 16. Future prospectsPersonalised medicine is an emerging field which will potentiallybring radical change to healthcare.It is important to create a better understanding of the value ofmolecular diagnostics both to cost effective health care andbetter patient outcomes in Europe. DM 10-2011 Copyright © Tekes
  • 17. Thank You!Tekes activitieswww.tekes.fi/enmerja.hiltunen@tekes.fi Copyright © Tekes